Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of G-202 as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma (G-202-003)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
GenSpera, Inc.
ClinicalTrials.gov Identifier:
NCT01777594
First received: January 18, 2013
Last updated: October 9, 2014
Last verified: October 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: January 2015
  Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)